When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the skin may be just as effective as traditional means of administration with ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Cambridge, Mass.-based Biogen had per-share earnings of $1.83 for the quarter, up from $1.71 a year ago. Adjusted for one-time items, EPS came to $3.44, ahead of the $3.35 FactSet consensus.

Reports Q4 revenue $2.5B, consensus $2.42B. President and CEO Christopher A. Viehbacher said: “We believe 2024 was an important year on our ...

Applications to refinance a home loan jumped 10% compared with the previous week and were 33% higher than the same week one ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen (NASDAQ:BIIB) stock traded flat as the company reports better than expected Q4 2024 financials, but its 2025 outlook ...

Biogen beat fourth-quarter earnings and sales expectations Wednesday, but Biogen stock could get hammered on its light earnings outlook.

Restaurant Brands International reported quarterly adjusted earnings per share of 81 cents and revenue of $2.3 billion.

Investors fled the company's stock in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's ...

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

It caps off the first full quarter with David Joyner, a longtime CVS executive, as CEO of the troubled retail drugstore chain ...